Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is adamantinoma?
Adamantinoma is an unusual low-grade bone cancer that develops in the middle of a long bone — about 85% of the time in the tibia (shin), and occasionally the jaw or forearm. It grows very slowly, often over many years, and frequently causes a painless swelling or a bowing of the shin long before it is diagnosed. Under the microscope it contains both bone-forming and epithelial-looking cells, and it is closely related to a benign condition called osteofibrous dysplasia. Because adamantinoma is resistant to both radiation and chemotherapy, the entire treatment rests on removing it surgically with a wide, clean margin. The outlook is generally very good, but the tumor has a stubborn tendency to come back locally if any cells are left behind, and a minority can eventually spread — most often to the lungs and lymph nodes — sometimes years later.
The main types
Doctors group adamantinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic adamantinoma | The typical adult form: a slow-growing tumor in the middle of the shin bone, sometimes causing the bone to bow. |
| Osteofibrous dysplasia–like (differentiated) adamantinoma | A less aggressive, childhood form that overlaps with the benign condition osteofibrous dysplasia. It is watched closely and may be treated more conservatively. |
| Dedifferentiated adamantinoma | A rare, more aggressive form with higher-grade cells and a greater risk of spreading. |
Staging, in plain terms
Adamantinoma is staged like other bone tumors, by how large it is, whether it has broken out of the bone, and whether it has spread. Because it is low-grade and slow, most are found while still confined to the original bone.
| Bone-sarcoma extent + grade (AJCC/Enneking) | What it generally means |
|---|---|
| Localized, intraosseous | The tumor is contained within the shin bone. This is how most adamantinomas are found, and complete removal gives an excellent outlook. |
| Locally advanced | The tumor has grown through the bone's outer shell into surrounding soft tissue, making complete removal more demanding. |
| Recurrent | The tumor has returned at the original site, usually because some cells were left behind. Local recurrence is a known challenge with this cancer. |
| Metastatic | The cancer has spread, most often to the lungs or lymph nodes. This happens in a minority of patients, sometimes many years after the first treatment. |
The standard of care
Adamantinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Wide surgical resection (the only cure)
Removing the whole tumor with a generous rim of healthy bone is essential. Because adamantinoma resists other treatments, the completeness of surgery is what determines the outcome.
Limb-salvage reconstruction
After removing the diseased segment of shin, surgeons rebuild the bone with a graft or implant. This saves the leg in most patients; amputation is reserved for tumors that involve major nerves and vessels.
Long-term surveillance
Because this cancer can recur locally or spread to the lungs years later, regular follow-up scans of the leg and chest continue well beyond the first few years.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. Adamantinoma cells repair this damage very effectively, which is why radiation rarely controls the tumor and surgery is the cure. In the uncommon situation where a tumor cannot be fully removed, modern image-guided radiation can still be used to slow it or relieve pain, delivering carefully shaped beams to the target over a series of short, painless sessions that leave no radioactivity behind.
The main ways radiation is delivered for adamantinoma:
Radiation — not standard
Adamantinoma is radioresistant, so radiation is not part of routine cure. It may be considered only when surgery cannot remove the tumor completely or to ease symptoms from spread that can't be operated on.
Targeted therapy for metastatic disease
For the rare patient with widespread disease that cannot be removed, targeted drugs such as sunitinib have been reported to help in case studies, since standard chemotherapy is generally ineffective.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Long-term outcomes of adamantinoma and osteofibrous dysplasia: Long-term series confirm that wide surgical resection with clear margins is the mainstay, with excellent survival but a notable rate of local recurrence when margins are inadequate.[1]
Long-term outcome series, ScienceDirect (J Bone Oncol)
Adamantinoma overall survival: Reviews report roughly 85% overall survival at 10 years, with metastasis occurring in up to about 30% of patients over the course of the disease, underscoring the need for prolonged follow-up.[2]
Adamantinoma review (Wikipedia / OrthoInfo AAOS)
Metastatic adamantinoma responding to sunitinib: A case report described meaningful response of metastatic adamantinoma to the targeted drug sunitinib, offering an option where conventional chemotherapy and radiation fail.[3]
Case report, PMC5005543
Common questions
Why can't radiation or chemotherapy treat my adamantinoma? This tumor is naturally resistant to both. Its cells repair radiation damage and shrug off standard chemotherapy. That is why complete surgical removal is the treatment that cures it, and why getting clean surgical margins matters so much.
Will I lose my leg? Usually not. Most adamantinomas can be removed with limb-salvage surgery that rebuilds the shin bone. Amputation is reserved for tumors that have wrapped around the main nerves and blood vessels.
Could it come back? It can return at the original site if any cells were left behind, and a minority spread to the lungs — sometimes years later. That's why your team will keep checking your leg and chest with scans for a long time after surgery.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.